Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Age
30 - No limit years
Sex
ALL
Healthy Volunteers
No
Site 284
Huntsville, Alabama, United States
Site 274
Little Rock, Arkansas, United States
Site 283
Fountain Valley, California, United States
Site 277
La Jolla, California, United States
Site 271
San Francisco, California, United States
Site 279
Fort Lauderdale, Florida, United States
Site 293
Gainsville, Florida, United States
Site 282
Port Charlotte, Florida, United States
Site 285
Sunrise, Florida, United States
Site 273
Tampa, Florida, United States
Start Date
June 1, 2006
Primary Completion Date
December 1, 2007
Completion Date
December 1, 2007
Last Updated
August 29, 2008
468
ACTUAL participants
pardoprunox
DRUG
Pardoprunox
DRUG
Pardoprunox
DRUG
Placebo
DRUG
Lead Sponsor
Solvay Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions